Glaucoma Foundation launches annual innovation award

Article

The Glaucoma Foundation in the US has created an award scheme for innovation and excellence in glaucoma, recognizing the contribution of individuals who have "played a unique and significant role in promoting the medicine and science of glaucoma".

The Glaucoma Foundation in the US has created an award scheme for innovation and excellence in glaucoma, recognizing the contribution of individuals who have “played a unique and significant role in promoting the medicine and science of glaucoma”.

The first recipient of the annual award is Robert Ritch, MD, who founded The Glaucoma Foundation in 1984 and currently serves as the Foundation’s medical director and chairman of the scientific advisory board.

Dr Ritch - who has co-authored six books and over 1200 medical and scientific papers, book chapters, articles and abstracts on the subject of glaucoma, as well as holding the Shelley and Steven Einhorn Distinguished Chair in Ophthalmology and the post of Surgeon Director and Chief of Glaucoma Services at the New York Eye & Ear Infirmary, and Professor of Clinical Ophthalmology at The New York Medical College, Valhalla, New York ­- will receive the award at The Glaucoma Foundation’s annual benefit gala, the Black and White Ball.

In addition to the Award for Innovation and Excellence in Glaucoma, The Glaucoma Foundation also sponsors two other annual accolades: The Kitty Carlisle Hart Award of Merit for Lifetime Achievement and the Corporate Visionary Award.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.